GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A4657 Jatrorrhizine chloride -
A4659 Vabicaserin hydrochloride -
A4711 Tetrahydro-β-carboline -
A4744 PCPA methyl ester hydrochloride -
A4798 Naftidrofuryl oxalate -
A8974 G-Protein antagonist peptide TFA -
A8975 CTOP TFA -
A8991 TolazolineSummary: An α2-adrenergic receptor antagonist -
A8999 AZA1 -
A9025 Tecadenoson (CVT-510)
